# Aesku, Inc.

- Location (FDA's records): Miami, FL
- FDA decisions: 6 (2003–2006): 6 510(k) clearances
- Product codes: MSV (1), MVM (1), NBT (1), LJM (1), LLL (1), MID (1)
- Predicates its devices cite: 0 (0 its own); citations of its devices by later devices: 3 (0 its own)
- Recalls linked to its devices: 1 (0 Class I)
- Data: FDA decisions to Oct 25, 2026; recalls to Oct 12, 2026

## Firms that cite its devices most
- Sqi Diagnostics Systems: 1 (https://510kreport.com/company/sqi-diagnostics-systems)
- Gold Standard Diagnostics: 1 (https://510kreport.com/company/gold-standard-diagnostics)
- Grifols USA, LLC: 1 (https://510kreport.com/company/grifols-usa)

## Its most-cited devices
- K042644: Aeskulisa TTG a and Aeskulisa TTG G (2005), cited by 2
- K040953: Aeskulisa Ana Hep-2 (2004), cited by 1

## Recent decisions
- K062217: Aeskulska BETA2-Glyco-a (Dec 13, 2006)
- K051492: Aeskulisa Asca a (Nov 14, 2005)
- K042644: Aeskulisa TTG a and Aeskulisa TTG G (Jun 1, 2005)
- K040953: Aeskulisa Ana Hep-2 (Jun 23, 2004)
- K040463: Aeskulisa Cardiolipin Agm (May 12, 2004)
- K032469: Aeskulisa Ana 8PRO (Dec 16, 2003)

Source page: https://510kreport.com/company/aesku